This trial is testing a new chemotherapy drug to treat AML. They are trying to find the best dose of the drug to minimize side effects while still being effective.
1 Primary · 8 Secondary · Reporting Duration: From the first date of intervention until the first documented progression or the date of death from any causes, whichever came first, assessed up to 100 months
Experimental Treatment
24 Total Participants · 4 Treatment Groups
Primary Treatment: Calaspargase pegol-mknl · No Placebo Group · Phase 1
Age 18 - 65 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: